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extracorporeal photopheresis. His jaundice and his
skin rash resolved, and an MP taper was started. Three
weeks later (July 24, 2007) his MP dose was down to 32
mg/day. On August 1, 2007, a follow-up FDG PET-
CT scan on that day showed dramatic and complete
resolution of the tracer uptake in the multifocal mar-
row-based lesions as well as resolution of his retroper-
itoneal adenopathy. The lytic lesions in the marrow
demonstrated interval calcification in keeping with re-
sponse to treatment (Figure 1B). At that time, he was
receiving low-dose MP (8 mg/day), tacrolimus (1 mg
every other day), and weekly extracorporeal photophe-
resis. A follow-up bone marrow biopsy (August 17,
2007) showed a hypocellular marrow and no evidence
of HL infiltration. At that time the patient’s MP dose
had been further reduced to 4 mg/day. At his latest
follow-up (October 2, 2007), his HL remains in clini-
cal remission. His MP dose remains 4 mg/day, and his
tacrolimus dose is 0.5 mg every other day.
We believe this case provides vivid, objective doc-
umentation that a powerful graft-versus-HL effect ex-
ists even in patients with disseminated and extensive
disease (including marrow involvement), albeit over-
lapping in this case with severe skin and hepatic
GVHD. Although it cannot entirely be ruled out
that steroid therapy started for GVHD may have con-
tributed to the most recent response, this patient was
known to have advanced, highly refractory disease.
Such a rapid and generalized response to single-agent
methylprednisolone is unlikely. In addition, his meth-
ylprednisolone dose was quite low at the time of his
FDG PET-CT restaging and repeat marrow biopsy,
and his overall clinical course supports the presence
of a graft-versus-HL effect. The immunologic mecha-
nisms underlying this effect are not clear. Whether and
how this effect can be harnessed and modulated in
a more selective and clinically useful fashion deserves
further study.
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Lymphoma Effect
T cell non-Hodgkin lymphomas (TNHL) are an
uncommon and heterogeneous group of lymphoid
malignancies characterized by a poor prognosis.
They usually present with advanced-stage disease
and high International Prognostic Index (IPI) score
[1]. Patients with TNHL treated with conven-
tional-dose chemotherapy alone in general have
Letters to the Editor 481inferior overall survival (OS) and event-free survival
compared to those with diffuse large B cell lym-
phoma [2]. High-dose therapy and autologous he-
matopoietic stem cell transplantation (HSCT) in
relapsed or refractory patients have produced 3-yr
OS and progression free survival (PFS) rates of
35%-58% and 28%-50% respectively [1,3-5]. These
modalities are however not curative for majority of
patients with TNHL. Experience with allogeneic
HSCT in TNHL is limited, whereas the evidence
for graft-versus-T cell lymphoma effect is scant
[6,7].
Between May 1997 to February 2007, 14 pa-
tients with peripheral T cell lymphoma (PTCL), di-
agnosed according to World Health Organization
lymphoma classification [8], underwent allogeneic
HSCT at our institution. Patients with ALK1 posi-
tive anaplastic large cell lymphoma (ALCL) were ex-
cluded from this analysis. Baseline and treatment
characteristics of the patients are shown in Table 1.
There were 11 male and 3 female patients with a me-
dian age of 43 ys (range 30-52). Histology included
PTCL unspecified (n 5 5), angioimmunoblastic T-
cell lymphoma (n 5 4), ALCL (n 5 2), extranodal
NK/T-cell lymphoma, nasal type (n 5 2), and pan-
niculitis like T-cell lymphoma (n 5 1). Eight pa-
tients (57%) had chemosensitive disease, whereas 6
had high or intermediate/high age-adjusted IPI
score. Eleven (78%) had advanced stage (III-IV) dis-
ease at transplantation. The median number of prior
chemotherapy regimens was 3 (range 1-4). Median
time from diagnosis to allogeneic HSCT was 12
mos. Donors included matched siblings (n 5 9) or
unrelated donors (n 5 5) (MUD). Eight and 6
patients received myeloablative (MA) and reduced
intensity conditioning (RIC) respectively. Antithy-
mocyte globulin (ATG) was administered as part
of conditioning regimen in 3 RIC patients.
Median number of CD341 cells infused was 5.11
 106 cells/Kg. Median time to neutrophil and plate-
let engraftment was 15 and 24 d respectively. Rates of
grade II-IV and III-IV acute graft-versus-host disease
(aGVHD) were 50% (n 5 7) and 21% (n 5 3) respec-
tively. Seven patients developed chronic GVHD
(cGVHD). Median follow-up is 34 m (range 10-
127mos). Among 12 patients evaluable for response
assessment, 8 achieved complete remission (CR) and
4 patients had partial remission (PR) after allograft-
ing. Two and 4 patients with refractory disease
(RD) and PR before allografting respectively, were
in CR immediately following allogeneic HSCT,
whereas 3 patients with RD achieved PR following
allogeneic HSCT. Day 1100 and overall non-relapse
mortality (NRM) rates were 28% and 57%, respec-
tively. Cause of death included sepsis (n 5 2), invasive
fungal infections in patients with GVHD (n 5 2),
GVHD (n 5 2), disease progression (n 5 1), suddencardiac death (n 5 1), and post-transplant lymphopro-
liferative disorder (n 5 1). Cumulative incidence of re-
lapse at 3 yrs adjusted for competing risks (non-relapse
mortality) was 69%. Kaplan-Meier estimates of 3-yr
OS and PFS were 35% and 31%, respectively (Fig-
ure 1). On univariate analysis RIC was associated
with improved OS (P 5 .03), but not PFS (P 5 .12).
Table 1. Baseline and treatment characteristics of patients
Allogeneic-HSCT
N 5 14 (%)
Sex
Male
Female
Median age, yrs (range) 43 (30-52)
Histology
PTCL-NOS 5 (36)
Angioimmunoblastic T cell lymphoma 4 (28)
Anaplastic large cell lymphoma 2 (14)
Extranodal NK/T cell lymphoma, nasal
type
2 (14)
Panniculitis like T cell lymphoma 1 (7)
Stage at diagnosis
I 3 (21)
II -
III 3 (21)
IV 8 (57)
Bone marrow involvement
Yes 7 (50)
No 7 (50)
aaIPI Score
Low 1 (7)
Low/intermediate 7 (50)
High/intermediate 3 (21)
High 3 (21)
Median number of prior therapies (range) 3 (1-4)
Prior autologous transplantation
Yes 2 (14)
No 12 (86)
Donor type
HLA-identical sibling donor 9 (64)
Matched unrelated donor 5 (36)
Stem cell source
Bone marrow 2 (14)
Peripheral blood 12 (86)
GVHD prophylaxis
Cyclosporine/MTX 9 (64)
Tacrolimus/MTX 5 (36)
Conditioning regimen
Myeloablative (Bu/Cy) 8 (57)
Reduced intensity conditioning (Flu/Bu) 6 (43)
Disease status at transplantation
CR2 1 (7)
CR3 2 (14)
PR1 3 (21)
PR2 2 (14)
Refractory disease 6 (43)
aaIPI indicates age adjusted International Prognostic Index; Bu/Cy,
busulfan/cyclophosphamide; CR, complete remission; Flu/Bu, flu-
darabine/busulfan; GVHD, graft-versus-host disease; HSCT,
hematopoietic stem cell transplantation; MTX, methotrexate;
PTCL-NOD, peripheral T cell lymphoma-not otherwise speci-
fied; PR, partial remission.
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age adjusted IPI score, marrow involvement, chemo-
sensitivity, prior treatment, and donor type (matched
sibling vs. MUD) on OS and PFS was seen (P .
0.05). However, on multivariate logistic regression
analysis, no significant improvement in OS with RIC
was found (P 5 .99). Interestingly, 1 patient in PR
after MA transplantation converted to CR on tapering
immunosuppression. Immunosuppression was tapered
in a second (RIC) patient at time of disease progres-
sion, which resulted in prolonged CR. Only 3 patients
experienced disease relapse. Disease relapse was her-
alded in 2 patients with loss of full donor chimerism.
Notably, no patient surviving beyond one year after
transplantation developed any evidence of disease
progression.
Conventional dose chemotherapy and autologous
HSCT do not appear to be curative for the majority
of patients with TNHL [1,2,4]. The experience with
allogeneic HSCT in TNHL is limited with spare
evidence of graft-versus-T cell lymphoma effect after
allografting. Rodriguez et al [4] reported 3-yr OS
and PFS of 29% and 14% respectively in 7 patients
who received allogeneic HSCT. Kahl et al. [6] reported
1-y survival probability of 40% following allografting in
5 patients. No objective evidence of graft-versus-lym-
phoma effect was noted in these small patient series.
Recently, Australasian Bone Marrow Transplant Recip-
ient Registry and the British Society of Bone Marrow
Transplantation database revealed 3-y OS and PFS of
39% and 33%, respectively in 18 patients with allograft-
ing [7]. This study showed no evidence of graft-versus-
lymphoma effect in PTCL patients. Moreover, relapse
rates following allografting were similar to those seen
following autologous HSCT. Unlike these studies, the
temporal association of loss of full donor chimerism
and disease relapse, as well as clear evidence of disease
Figure 1. Kaplan-Meier estimates of overall survival following
allogeneic hematopoietic stem cell transplantation in patients with
peripheral T cell lymphoma (n514).remission with tapering of immunosuppressive medica-
tions in our patients suggests that allogeneic HSCT is
associated with a relevant graft-versus-T cell lym-
phoma effect in TNHL. Five patients in our study
with chemo-refractory disease at the time of transplan-
tation showed either a CR or PR following allografting,
again supporting immune recognition of TNHL. No
disease relapse in patients surviving beyond 1 y in our
series hints at the curative potential of this modality.
In fact Corradini et al [9] reported impressive 3-yr
OS and PFS rates of 81% and 64% in TNHL patients
undergoing RIC HSCT. Notably donor lymphocyte
infusions (DLI) given to 4 patients at the time of
disease progression produced disease response in 2 pa-
tients. The sustained response to withdrawing immu-
nosuppression in our series precluded the use of DLI.
However, these observations suggest that immune
competent cells in the allograft can exert tumor-specific
immune responses in TNHL. In conclusion, our lim-
ited and preliminary results demonstrate that alloge-
neic HSCT is associated with clinical evidence of
graft-versus-lymphoma effect in TNHL. Larger, pro-
spective studies employing RIC earlier in the disease
course are warranted.
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